Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2016 | Research

CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells

Authors: Aki Tanouchi, Keisuke Taniuchi, Mutsuo Furihata, Seiji Naganuma, Ken Dabanaka, Masashi Kimura, Ryohei Watanabe, Takuhiro Kohsaki, Takahiro Shimizu, Motoaki Saito, Kazuhiro Hanazaki, Toshiji Saibara

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Abstract

Background

Coiled-Coil Domain Containing 88A (CCDC88A) was identified as a substrate of the serine/threonine kinase Akt that is capable of binding to the actin cytoskeleton. The aim of this study was to investigate the potential role of CCDC88A in the migration and invasiveness of pancreatic ductal adenocarcinoma (PDAC) cells.

Methods

Immunohistochemistry was performed to determine whether high CCDC88A expression in human PDAC tissues is correlated with poor prognosis. Immunoprecipitation, immunoblotting and immunocytochemistry were performed to determine the intracellular distribution of CCDC88A, and its association with the serine/threonine kinase Akt and actin-filaments in PDAC cells. Phosphoprotein array analysis was performed to determine CCDC88A-associated intracellular signaling pathways. Finally, immunofluorescence analyses and Matrigel invasion assays were performed to examine the effects of CCDC88A on the formation of cell protrusions and PDAC cell invasion.

Results

Expression of CCDC88A in PDAC tissue was significantly correlated with overall survival. CCDC88A was co-localized with peripheral actin structures in cell protrusions of migrating PDAC cells. Knockdown of CCDC88A inhibited the migration and invasiveness of PDAC cells through a decrease in cell protrusions. Although CCDC88A has been previously reported to be a binding partner and substrate of Akt, the level of active Akt was not associated with the translocation of CCDC88A towards cell protrusions. CCDC88A-dependent promotion of cell migration and invasiveness was not modulated by Akt signaling. Knockdown of CCDC88A decreased phosphorylated Src and ERK1/2 and increased phosphorylated AMPK1 in PDAC cells. Knockdown of AMPK1 inhibited the migration and invasiveness of PDAC cells. The combined data suggest that CCDC88A may be a useful marker for predicting the outcome of patients with PDAC and that CCDC88A can promote PDAC cell migration and invasion through a signaling pathway that involves phosphorylation of Src and ERK1/2 and/or dephosphorylation of AMPK1.

Conclusions

CCDC88A was accumulated in cell protrusions, contributed to the formation of membrane protrusions, and increased the migration and invasiveness of PDAC cells.

Available only for authorised users

Enomoto A, Murakami H, Asai N, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 2005;9(3):389–402.CrossRefPubMed

Weng L, Enomoto A, Ishida-Takagishi M, et al. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci. 2010;101(4):836–42.CrossRefPubMed

Kim D, Kim S, Koh H, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001;15(11):1953–62.CrossRefPubMed

Enomoto A, Ping J, Takahashi M. Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann N Y Acad Sci. 2006;1086:169–84.CrossRefPubMed

Ghosh P, Garcia-Marcos M, Bornheimer SJ, et al. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol. 2008;182(2):381–93.CrossRefPubMedPubMedCentral

Kitamura T, Asai N, Enomoto A, et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol. 2008;103(3):329–37.CrossRef

Jiang P, Enomoto A, Jijiwa M, et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008;68(5):1310–8.CrossRefPubMed

Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639–50.CrossRefPubMed

Garcia-Marcos M, Ghosh P, Farquhar MG. GIV is a nonreceptor GEF for G alpha i with a unique motif that regulates Akt signaling. Proc Natl Acad Sci U S A. 2009;106(9):3178–83.CrossRefPubMedPubMedCentral

10.

Baumgart M, Heinmöller E, Horstmann O, et al. The genetic basis of sporadic pancreatic cancer. Cell Oncol. 2005;27(1):3–13.PubMedPubMedCentral

11.

Taniuchi K, Furihata M, Hanazaki K, et al. IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Oncotarget. 2014;5(16):6832–45.CrossRefPubMedPubMedCentral

12.

Taniuchi K, Furihata M, Saibara T. KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells. Neoplasia. 2014;16(12):1082–93.CrossRefPubMedPubMedCentral

13.

Miyazawa Y, Uekita T, Hiraoka N, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010;70(12):5136–46.CrossRefPubMed

14.

Koch HJ, Hau P. ROC analysis as an additional method to characterize time to event data. Pathol Oncol Res. 2005;11(1):50–2.CrossRefPubMed

15.

Taniuchi K, Nishimori I, Hollingsworth MA. Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP. Cancer Res. 2011;71(3):895–905.CrossRefPubMed

16.

Taniuchi K, Yokotani K, Saibara T. BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1. Neoplasia. 2012;14(5):440–50.CrossRefPubMedPubMedCentral

17.

Tsuboi M, Taniuchi K, Furihata M, et al. Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells. Pancreatology. 2016;16(5):905–16.CrossRefPubMed

18.

Gallo G, Letourneau PC. Regulation of growth cone actin filaments by guidance cues. J Neurobiol. 2004;58(1):92–102.CrossRefPubMed

19.

Roberts Jr CT. Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Endocr J. 1996;43(Suppl):S49–55.CrossRefPubMed

20.

Goto M, Iwase A, Harata T, et al. IGF1-induced AKT phosphorylation and cell proliferation are suppressed with the increase in PTEN during luteinization in human granulosa cells. Reproduction. 2009;137(5):835–42.CrossRefPubMed

21.

Ghosh P, Beas AO, Bornheimer SJ, et al. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell. 2010;21(13):2338–54.CrossRefPubMedPubMedCentral

22.

Bamburg JR, McGough A, Ono S. Putting a new twist on actin: ADF/cofilins modulate actin dynamics. Trends Cell Biol. 1999;9(9):364–70.CrossRefPubMed

23.

Eiseler T, Döppler H, Yan IK, et al. Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol. 2009;11(5):545–56.CrossRefPubMedPubMedCentral

24.

Farkas A, Szatmari E, Orbok A, et al. Hyperosmotic mannitol induces Src kinase-dependent phosphorylation of beta-catenin in cerebral endothelial cells. J Neurosci Res. 2005;80(6):855–61.CrossRefPubMed

25.

Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001;98(13):7319–24.CrossRefPubMedPubMedCentral

26.

Levin VA. Basis and importance of Src as a target in cancer. Cancer Treat Res. 2004;119:89–119.CrossRefPubMed

27.

Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–75.CrossRefPubMedPubMedCentral

28.

Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010;6(3):457–70.CrossRefPubMedPubMedCentral

29.

Park HU, Suy S, Danner M, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009;8(4):733–41.CrossRefPubMedPubMedCentral

30.

Japan Pancreatic Society. Classification of pancreatic carcinoma. 2nd English ed., Kanehara & Co Tokyo; 2003.

31.

Sobin LH, Gospodarowicz MK, Witteknd C, editors. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009. p. 132–5.

32.

Iwamura T, Katsuki T, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19–9. Jpn J Cancer Res. 1987;78(1):54–62.PubMed

Title: CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells
Authors: Aki Tanouchi
Keisuke Taniuchi
Mutsuo Furihata
Seiji Naganuma
Ken Dabanaka
Masashi Kimura
Ryohei Watanabe
Takuhiro Kohsaki
Takahiro Shimizu
Motoaki Saito
Kazuhiro Hanazaki
Toshiji Saibara
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-016-0466-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo

Molecular targeted therapy for the treatment of gastric cancer

Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase

Trends and advances in tumor immunology and lung cancer immunotherapy

Activation of the JNK-c-Jun pathway in response to irradiation facilitates Fas ligand secretion in hepatoma cells and increases hepatocyte injury

Keynote webinar | Spotlight on antibody–drug conjugates in cancer